

BIO SKETCH

NAME : Xavier Guillonneau

POSITION TITLE : Chargé de Recherche Inserm

EDUCATION / TRAINING

INSTITUTION AND LOCATION	DEGREE	Month/Year	FIELD OF STUDY
Université Paris 6	Habilitation à Diriger des Recherches	2010	Ophthalmology
Université Paris 6	PhD	1997	Ophthalmology

POSITIONS AND EMPLOYMENTS

MONTH AA – MONTH BB	Name of the Institution - Title of the Position
Since 2012	Institut de la Vision, Team 14, Group leader (ischemic retinopathies) Charge de Recherche classe 1 Inserm
2009-2012	UMRS 872 Team 21 (F.Sennlaub) : Ocular degenerative and neovascular processes; Centre de Recherche des Cordeliers, Paris. Senior Researcher
1997-2000	INSERM U450 & 592 (O. Goureau) Molecular mechanisms of retinal development Junior Researcher (CR2)
1994-1997	Jules Stein Eye Institute, UCLA, USA, Deborah Farber Post doctorat:
1994	INSERM U450 Ph.D. in molecular and cellular biology Université Paris 5.

Scientific Interests :

Dr. Xavier Guillonneau is leading a group in Team 14 focused on the involvement of inflammatory mechanisms in retinal vascular diseases (diabetic retinopathy and retinopathy of prematurity) and in neurodegenerative processes associated with age related macular degeneration. Xavier Guillonneau is working for more than 15 years in the field of ophthalmology. He had expertise in eye pathophysiology (PhD, UPMC 1997), genetic (Postdoctoral fellowship at The Jules Stein Intstitute, UCLA, USA), retinal development (senior staff researcher at INSERM) and in inflammatory processes leading to degeneration and vascular remodeling. Dr. Guillonneau has published over 30 articles in peer-reviewed journals including Human Molecular Genetics, Journal of Neuroscience, Developmental Biology, Circulation, PLoS Medicine, Angiogenesis, and EMBO Mol Med

Le Dr Guillonneau est responsable d'un groupe au sein de l'équipe 14 focalisé sur l'implication des mécanismes inflammatoires dans les pathologies vasculaires de la rétine (rétinopathie diabétique, et rétinopathie du prématuré) ainsi que dans les phénomènes neurodégénératifs associés à la dégénérescence maculaire liée à l'âge. Le Dr Guillonneau travaille depuis 15 ans dans le domaine de l'ophtalmologie. Il a acquis une expertise reconnue dans le domaine de la physiopathologie oculaire, du développement rétinien et dans les phénomènes inflammatoires conduisant à la dégénérescence et au remodelage vasculaire. Le docteur Guillonneau a publié plus de 30 articles dans des revues a comité de lecture dont Human Molecular Genetics, Journal of Neuroscience, Developmental Biology, Circulation, PLoS Medecine, Angiogenesis, et EMBO Mol Med .

Other Experiences and Professional Memberships :

- 1998- Member, Association for Research in Vision and Ophthalmology
- 2012- Academic Editor, PLoS One

Selected Peer-reviewed Publications:

- 2013 Sennlaub, F., C. Auvynet, B. Calippe, S. Lavalette, L. Poupel, S. J. Hu, E. Dominguez, S. Camelo, O. Levy, E. Guyon, N. Saederup, I. F. Charo, N. V. Rooijen, E. Nandrot, J. L. Bourges, F. Behar-Cohen, J. A. Sahel, **X. Guillonneau**, W. Raoul and C. Combadiere (2013). "CCR2(+) monocytes infiltrate atrophic lesions in age-related macular disease and mediate photoreceptor degeneration in experimental subretinal inflammation in Cx3cr1 deficient mice." *EMBO Mol Med* 5(11): 1775-1793.
- Kermorvant-Duchemin, E., A. C. Pinel, S. Lavalette, D. Lenne, W. Raoul, B. Calippe, F. Behar-Cohen, J. A. Sahel, F. Sennlaub* and **X. Guillonneau*** (2013). "Neonatal hyperglycemia inhibits angiogenesis and induces inflammation and neuronal degeneration in the retina." *PLoS One* 8(11): e79545.
- 2012 Camelo, S., W. Raoul, S. Lavalette, B. Calippe, B. Cristofaro, O. Levy, M. Houssier, E. Sulpice, L. Jonet, C. Klein, E. Devezre, G. Thuret, A. Duarte, A. Eichmann, L. Leconte, **X. Guillonneau** and F. Sennlaub (2012). "Delta-like 4 inhibits choroidal neovascularization despite opposing effects on vascular endothelium and macrophages." *Angiogenesis* 15(4): 609-622.
- Lelièvre EC, Benayoun BA, Mahieu L, Roger JE, Sahel J-A, Sennlaub F, Veitia RA, Goureau O, **Guillonneau X**. 2012. A regulatory domain is required for Foxn4 activity during retinogenesis. *J Mol Neurosci* 46:315–323.
- 2011 Lavalette, S., W. Raoul, M. Houssier, S. Camelo, O. Levy, B. Calippe, L. Jonet, F. Behar-Cohen, S. Chemtob, **X. Guillonneau**, C. Combadiere and F. Sennlaub (2011). "Interleukin-1beta inhibition prevents choroidal neovascularization and does not exacerbate photoreceptor degeneration." *Am J Pathol* 178(5): 2416-2423.
- Lelièvre EC, Lek M, Boije H, Houille-Vernes L, Brajeul V, Slembrouck A, Roger JE, Sahel JA, Matter JM, Sennlaub F, Hallböök F, Goureau O, **Guillonneau X**. 2011. Ptf1a/Rbpj complex inhibits ganglion cell fate and drives the specification of all horizontal cell subtypes in the chick retina. *Dev Biol* 358:296–308.

2008 Houssier, M., Raoul, W., Lavalette, S., Keller, N., **Guillonneau, X.**, Baragatti, B., Jonet, L., Jeanny, J.C., Behar-Cohen, F., Coceani, F., Scherman, D., Lachapelle, P., Ong, H., Chemtob, S., and Sennlaub, F. 2008. CD36 deficiency leads to choroidal involution via COX2 down-regulation in rodents. *PLoS Med* 5:e39.

